FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1587304870> ?p ?o ?g. }

• W1587304870 endingPage "743" @default.
• W1587304870 startingPage "737" @default.
• W1587304870 abstract "The survival benefit of second-line chemotherapy with docetaxel in platinum-refractory patients with advanced esophageal cancer (AEC) remains unclear. A retrospective analysis of AEC patients with Eastern Cooperative Oncology Group performance status (PS) ≤ 2 was performed, and major organ functions were preserved, who determined to receive docetaxel or best supportive care (BSC) alone after failure of platinum-based chemotherapy. The post-progression survival (PPS), defined as survival time after disease progression following platinum-based chemotherapy, was analyzed by multivariate Cox regression analysis using factors identified as significant in univariate analysis of various 20 characteristics (age, sex, PS, primary tumor location, etc) including Glasgow prognostic score (GPS), which is a well-known prognostic factor in many malignant tumors. Sixty-six and 45 patients were determined to receive docetaxel and BSC between January 2007 and December 2011, respectively. The median PPS was 5.4 months (95% confidence interval [CI] 4.8–6.0) in the docetaxel group and 3.3 months (95% CI 2.5–4.0) in the BSC group (hazard ratio [HR] 0.56, 95% CI 0.38–0.84, P = 0.005). Univariate analysis revealed six significant factors: treatment, PS, GPS, number of metastatic organs, liver metastasis, and bone metastasis. Multivariate analysis including these significant factors revealed three independent prognostic factors: docetaxel treatment (HR 0.62, 95% CI 0.39–0.99, P = 0.043), better GPS (HR 0.61, 95% CI 0.46–0.81, P = 0.001), and no bone metastasis (HR 0.31, 95% CI 0.15–0.68, P = 0.003). There was a trend for PPS in favor of the docetaxel group compared with patients who refused docetaxel treatment in the BSC group (adjusted HR 0.61, 95% CI 0.29–1.29, P = 0.20). Docetaxel treatment may have prolonged survival in platinum-refractory patients with AEC." @default.
• W1587304870 created "2016-06-24" @default.
• W1587304870 creator A5023842343 @default.
• W1587304870 creator A5028248936 @default.
• W1587304870 creator A5028389456 @default.
• W1587304870 creator A5031710130 @default.
• W1587304870 creator A5038876397 @default.
• W1587304870 creator A5039675116 @default.
• W1587304870 creator A5045506047 @default.
• W1587304870 creator A5053509708 @default.
• W1587304870 creator A5054153658 @default.
• W1587304870 creator A5057450881 @default.
• W1587304870 creator A5058515534 @default.
• W1587304870 creator A5062990944 @default.
• W1587304870 creator A5072762614 @default.
• W1587304870 creator A5083303913 @default.
• W1587304870 creator A5089442498 @default.
• W1587304870 date "2014-06-11" @default.
• W1587304870 modified "2023-10-06" @default.
• W1587304870 title "Survival analysis of platinum-refractory patients with advanced esophageal cancer treated with docetaxel or best supportive care alone: a retrospective study" @default.
• W1587304870 cites W1970194999 @default.
• W1587304870 cites W1975239262 @default.
• W1587304870 cites W1979390240 @default.
• W1587304870 cites W1981989535 @default.
• W1587304870 cites W1988902102 @default.
• W1587304870 cites W1992033632 @default.
• W1587304870 cites W2015064506 @default.
• W1587304870 cites W2044720517 @default.
• W1587304870 cites W2059806781 @default.
• W1587304870 cites W2064690805 @default.
• W1587304870 cites W2078481325 @default.
• W1587304870 cites W2086140502 @default.
• W1587304870 cites W2092878111 @default.
• W1587304870 cites W2094712821 @default.
• W1587304870 cites W2108661938 @default.
• W1587304870 cites W2111797676 @default.
• W1587304870 cites W2113814947 @default.
• W1587304870 cites W2114734455 @default.
• W1587304870 cites W2131343368 @default.
• W1587304870 cites W2132871418 @default.
• W1587304870 cites W2138098788 @default.
• W1587304870 cites W2154664762 @default.
• W1587304870 cites W2157215374 @default.
• W1587304870 doi "https://doi.org/10.1111/dote.12246" @default.
• W1587304870 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24917486" @default.
• W1587304870 hasPublicationYear "2014" @default.
• W1587304870 type Work @default.
• W1587304870 sameAs 1587304870 @default.
• W1587304870 citedByCount "4" @default.
• W1587304870 countsByYear W15873048702016 @default.
• W1587304870 countsByYear W15873048702022 @default.
• W1587304870 countsByYear W15873048702023 @default.
• W1587304870 crossrefType "journal-article" @default.
• W1587304870 hasAuthorship W1587304870A5023842343 @default.
• W1587304870 hasAuthorship W1587304870A5028248936 @default.
• W1587304870 hasAuthorship W1587304870A5028389456 @default.
• W1587304870 hasAuthorship W1587304870A5031710130 @default.
• W1587304870 hasAuthorship W1587304870A5038876397 @default.
• W1587304870 hasAuthorship W1587304870A5039675116 @default.
• W1587304870 hasAuthorship W1587304870A5045506047 @default.
• W1587304870 hasAuthorship W1587304870A5053509708 @default.
• W1587304870 hasAuthorship W1587304870A5054153658 @default.
• W1587304870 hasAuthorship W1587304870A5057450881 @default.
• W1587304870 hasAuthorship W1587304870A5058515534 @default.
• W1587304870 hasAuthorship W1587304870A5062990944 @default.
• W1587304870 hasAuthorship W1587304870A5072762614 @default.
• W1587304870 hasAuthorship W1587304870A5083303913 @default.
• W1587304870 hasAuthorship W1587304870A5089442498 @default.
• W1587304870 hasBestOaLocation W15873048701 @default.
• W1587304870 hasConcept C121608353 @default.
• W1587304870 hasConcept C126322002 @default.
• W1587304870 hasConcept C141071460 @default.
• W1587304870 hasConcept C143998085 @default.
• W1587304870 hasConcept C144301174 @default.
• W1587304870 hasConcept C167135981 @default.
• W1587304870 hasConcept C207103383 @default.
• W1587304870 hasConcept C2776694085 @default.
• W1587304870 hasConcept C2776907518 @default.
• W1587304870 hasConcept C2777783956 @default.
• W1587304870 hasConcept C2779013556 @default.
• W1587304870 hasConcept C2781190966 @default.
• W1587304870 hasConcept C38180746 @default.
• W1587304870 hasConcept C44249647 @default.
• W1587304870 hasConcept C50382708 @default.
• W1587304870 hasConcept C71924100 @default.
• W1587304870 hasConceptScore W1587304870C121608353 @default.
• W1587304870 hasConceptScore W1587304870C126322002 @default.
• W1587304870 hasConceptScore W1587304870C141071460 @default.
• W1587304870 hasConceptScore W1587304870C143998085 @default.
• W1587304870 hasConceptScore W1587304870C144301174 @default.
• W1587304870 hasConceptScore W1587304870C167135981 @default.
• W1587304870 hasConceptScore W1587304870C207103383 @default.
• W1587304870 hasConceptScore W1587304870C2776694085 @default.
• W1587304870 hasConceptScore W1587304870C2776907518 @default.
• W1587304870 hasConceptScore W1587304870C2777783956 @default.
• W1587304870 hasConceptScore W1587304870C2779013556 @default.
• W1587304870 hasConceptScore W1587304870C2781190966 @default.
• W1587304870 hasConceptScore W1587304870C38180746 @default.

• next